APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hematologic Oncology Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hematologic Oncology Treatment Market Outlook and Growth Opportunities 2026

30 December 2025191 pages

Choose your research edition.

Industry ResearchHematologic Oncology Treatment Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hematologic Oncology Treatment Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Hematologic Oncology Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hematologic Oncology Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Hematologic Oncology Treatment Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hematologic Oncology Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hematologic Oncology Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hematologic Oncology Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hematologic Oncology Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hematologic Oncology Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hematologic Oncology Treatment market include Bristol-Myers Squibb, Gilead Sciences, AstraZeneca, AbbVie, Amgen, Pfizer, Roche, Novartis and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hematologic Oncology Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hematologic Oncology Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hematologic Oncology Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hematologic Oncology Treatment market.

Hematologic Oncology Treatment Segment by Company

Bristol-Myers Squibb

Gilead Sciences

AstraZeneca

AbbVie

Amgen

Pfizer

Roche

Novartis

Johnson & Johnson

Takeda

Hematologic Oncology Treatment Segment by Type

Targeted Therapy

Chemotherapy

Immunotherapy

Other

Hematologic Oncology Treatment Segment by Application

Lymphoma

Multiple Myeloma

Leukemia

Others

Hematologic Oncology Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Hematologic Oncology Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hematologic Oncology Treatment key companies, revenue, market share, and recent developments.

3. To split the Hematologic Oncology Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hematologic Oncology Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hematologic Oncology Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Hematologic Oncology Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hematologic Oncology Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hematologic Oncology Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hematologic Oncology Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hematologic Oncology Treatment industry.

Chapter 3: Detailed analysis of Hematologic Oncology Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hematologic Oncology Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hematologic Oncology Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hematologic Oncology Treatment Industry Trends Table 2. Hematologic Oncology Treatment Industry Drivers Table 3. Hematologic Oncology Treatment Industry Opportunities and Challenges Table 4. Hematologic Oncology Treatment Industry Restraints Table 5. Global Hematologic Oncology Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hematologic Oncology Treatment Revenue Share by Company (2021-2026) Table 7. Global Hematologic Oncology Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hematologic Oncology Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Hematologic Oncology Treatment Company, Product Type & Application Table 10. Global Hematologic Oncology Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hematologic Oncology Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Targeted Therapy Table 15. Significant Companies of Chemotherapy Table 16. Significant Companies of Immunotherapy Table 17. Significant Companies of Other Table 18. Global Hematologic Oncology Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Hematologic Oncology Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Hematologic Oncology Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Hematologic Oncology Treatment Sales Value Share by Type (2021-2026) Table 22. Global Hematologic Oncology Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Lymphoma Table 24. Significant Companies of Multiple Myeloma Table 25. Significant Companies of Leukemia Table 26. Significant Companies of Others Table 27. Global Hematologic Oncology Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Hematologic Oncology Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Hematologic Oncology Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Hematologic Oncology Treatment Sales Value Share by Application (2021-2026) Table 31. Global Hematologic Oncology Treatment Sales Value Share by Application (2027-2032) Table 32. Global Hematologic Oncology Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Hematologic Oncology Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Hematologic Oncology Treatment Sales Value Share by Region (2021-2026) Table 35. Global Hematologic Oncology Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Hematologic Oncology Treatment Sales Value Share by Region (2027-2032) Table 37. Global Hematologic Oncology Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Hematologic Oncology Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Hematologic Oncology Treatment Sales Value Market Share by Country (2021-2026) Table 40. Global Hematologic Oncology Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Hematologic Oncology Treatment Sales Value Market Share by Country (2027-2032) Table 42. Bristol-Myers Squibb Company Information Table 43. Bristol-Myers Squibb Business Overview Table 44. Bristol-Myers Squibb Hematologic Oncology Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Bristol-Myers Squibb Hematologic Oncology Treatment Product Portfolio Table 46. Bristol-Myers Squibb Recent Development Table 47. Gilead Sciences Company Information Table 48. Gilead Sciences Business Overview Table 49. Gilead Sciences Hematologic Oncology Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Gilead Sciences Hematologic Oncology Treatment Product Portfolio Table 51. Gilead Sciences Recent Development Table 52. AstraZeneca Company Information Table 53. AstraZeneca Business Overview Table 54. AstraZeneca Hematologic Oncology Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. AstraZeneca Hematologic Oncology Treatment Product Portfolio Table 56. AstraZeneca Recent Development Table 57. AbbVie Company Information Table 58. AbbVie Business Overview Table 59. AbbVie Hematologic Oncology Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. AbbVie Hematologic Oncology Treatment Product Portfolio Table 61. AbbVie Recent Development Table 62. Amgen Company Information Table 63. Amgen Business Overview Table 64. Amgen Hematologic Oncology Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Amgen Hematologic Oncology Treatment Product Portfolio Table 66. Amgen Recent Development Table 67. Pfizer Company Information Table 68. Pfizer Business Overview Table 69. Pfizer Hematologic Oncology Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Pfizer Hematologic Oncology Treatment Product Portfolio Table 71. Pfizer Recent Development Table 72. Roche Company Information Table 73. Roche Business Overview Table 74. Roche Hematologic Oncology Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Roche Hematologic Oncology Treatment Product Portfolio Table 76. Roche Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis Hematologic Oncology Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Novartis Hematologic Oncology Treatment Product Portfolio Table 81. Novartis Recent Development Table 82. Johnson & Johnson Company Information Table 83. Johnson & Johnson Business Overview Table 84. Johnson & Johnson Hematologic Oncology Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Johnson & Johnson Hematologic Oncology Treatment Product Portfolio Table 86. Johnson & Johnson Recent Development Table 87. Takeda Company Information Table 88. Takeda Business Overview Table 89. Takeda Hematologic Oncology Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Takeda Hematologic Oncology Treatment Product Portfolio Table 91. Takeda Recent Development Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Hematologic Oncology Treatment Product Image Figure 2. Global Hematologic Oncology Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hematologic Oncology Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Hematologic Oncology Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Targeted Therapy Image Figure 8. Chemotherapy Image Figure 9. Immunotherapy Image Figure 10. Other Image Figure 11. Global Hematologic Oncology Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Hematologic Oncology Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Hematologic Oncology Treatment Sales Value Share by Type (2021-2032) Figure 14. Lymphoma Image Figure 15. Multiple Myeloma Image Figure 16. Leukemia Image Figure 17. Others Image Figure 18. Global Hematologic Oncology Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Hematologic Oncology Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Hematologic Oncology Treatment Sales Value Share by Application (2021-2032) Figure 21. Global Hematologic Oncology Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Hematologic Oncology Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Hematologic Oncology Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. North America Hematologic Oncology Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Hematologic Oncology Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Hematologic Oncology Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Hematologic Oncology Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Hematologic Oncology Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Hematologic Oncology Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. South America Hematologic Oncology Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Hematologic Oncology Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Hematologic Oncology Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Other
Applications
  • Lymphoma
  • Multiple Myeloma
  • Leukemia
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Gilead Sciences
  • AstraZeneca
  • AbbVie
  • Amgen
  • Pfizer
  • Roche
  • Novartis
  • Johnson & Johnson
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hematologic Oncology Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hematologic Oncology Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hematologic Oncology Treatment Market Dynamics
  1. 2.1 Hematologic Oncology Treatment Industry Trends
  2. 2.2 Hematologic Oncology Treatment Industry Drivers
  3. 2.3 Hematologic Oncology Treatment Industry Opportunities and Challenges
  4. 2.4 Hematologic Oncology Treatment Industry Restraints
3 Hematologic Oncology Treatment Market by Company
  1. 3.1 Global Hematologic Oncology Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Hematologic Oncology Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Hematologic Oncology Treatment Company Ranking (2024-2026)
  4. 3.4 Global Hematologic Oncology Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Hematologic Oncology Treatment Company Product Type and Application
  6. 3.6 Global Hematologic Oncology Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hematologic Oncology Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hematologic Oncology Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hematologic Oncology Treatment Market by Type
  1. 4.1 Hematologic Oncology Treatment Type Introduction
  2. 4.1.1 Targeted Therapy
  3. 4.1.2 Chemotherapy
  4. 4.1.3 Immunotherapy
  5. 4.1.4 Other
  6. 4.2 Global Hematologic Oncology Treatment Sales Value by Type
  7. 4.2.1 Global Hematologic Oncology Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Hematologic Oncology Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global Hematologic Oncology Treatment Sales Value Share by Type (2021-2032)
5 Hematologic Oncology Treatment Market by Application
  1. 5.1 Hematologic Oncology Treatment Application Introduction
  2. 5.1.1 Lymphoma
  3. 5.1.2 Multiple Myeloma
  4. 5.1.3 Leukemia
  5. 5.1.4 Others
  6. 5.2 Global Hematologic Oncology Treatment Sales Value by Application
  7. 5.2.1 Global Hematologic Oncology Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Hematologic Oncology Treatment Sales Value by Application (2021-2032)
  9. 5.2.3 Global Hematologic Oncology Treatment Sales Value Share by Application (2021-2032)
6 Hematologic Oncology Treatment Regional Value Analysis
  1. 6.1 Global Hematologic Oncology Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hematologic Oncology Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hematologic Oncology Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hematologic Oncology Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hematologic Oncology Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Hematologic Oncology Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hematologic Oncology Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Hematologic Oncology Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hematologic Oncology Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hematologic Oncology Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hematologic Oncology Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Hematologic Oncology Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hematologic Oncology Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hematologic Oncology Treatment Sales Value Share by Country, 2025 VS 2032
7 Hematologic Oncology Treatment Country-level Value Analysis
  1. 7.1 Global Hematologic Oncology Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hematologic Oncology Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hematologic Oncology Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hematologic Oncology Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hematologic Oncology Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hematologic Oncology Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hematologic Oncology Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Hematologic Oncology Treatment Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences Hematologic Oncology Treatment Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 AstraZeneca
  14. 8.3.1 AstraZeneca Company Information
  15. 8.3.2 AstraZeneca Business Overview
  16. 8.3.3 AstraZeneca Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Hematologic Oncology Treatment Product Portfolio
  18. 8.3.5 AstraZeneca Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie Hematologic Oncology Treatment Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Hematologic Oncology Treatment Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Hematologic Oncology Treatment Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Hematologic Oncology Treatment Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Hematologic Oncology Treatment Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Johnson & Johnson
  50. 8.9.1 Johnson & Johnson Company Information
  51. 8.9.2 Johnson & Johnson Business Overview
  52. 8.9.3 Johnson & Johnson Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Johnson & Johnson Hematologic Oncology Treatment Product Portfolio
  54. 8.9.5 Johnson & Johnson Recent Developments
  55. 8.10 Takeda
  56. 8.10.1 Takeda Company Information
  57. 8.10.2 Takeda Business Overview
  58. 8.10.3 Takeda Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Takeda Hematologic Oncology Treatment Product Portfolio
  60. 8.10.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst